Results 151 to 160 of about 333,288 (246)

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Dopamine Agonist-Resistant Microprolactinoma-Mechanisms, Predictors and Management: A Case Report and Literature Review. [PDF]

J Clin Med, 2022
Szmygin H, Szydełko J, Matyjaszek-Matuszek B.   +2 more
europepmc   +1 more source

A rare case of galactocele in a patient with macroprolactinoma. The hypothetical role of poor compliance with dopamine agonist therapy. [PDF]

SAGE Open Med Case Rep
Abdelmahmuod EA, Bustanji H, Elhadd T.
europepmc   +1 more source

No Dopamine Agonist Modulation of Brain [¹⁸F]FEOBV Binding in Parkinson's Disease. [PDF]

Mol Pharm, 2022
Albin RL, Kanel P, van Laar T, van der Zee S, Roytman S, Koeppe RA, Scott PJH, Bohnen NI.   +7 more
europepmc   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

Dopamine Agonist Therapy Induced Fatal Pneumocephalus in Giant Prolactinoma. [PDF]

JCEM Case Rep
M H A, Lila AR, Karlekar M, Memon SS, Barnabas R, Bandgar T.   +5 more
europepmc   +1 more source

Dopamine /

, 2005
Dopamine is a major neurotransmitter of the brain involved in the control of movement, emotion, and cognition; disturbance in dopamine function is associated with disorders like Parkinsons disease, schizophrenia and attention deficit hyperactivity ...
Dunnett, S. B.(Stephen B.)
core  

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source

When treatment backfires: Dopamine agonist-induced CSF leaks in prolactinomas - Case series and systematic review. [PDF]

Brain Spine
Katsikas A, Gkalonakis I, Georgilaki V, Kyriakopoulos G, Markussis V, Tzanela M, Balakera C, Paleologos TS, Barkas K.   +8 more
europepmc   +1 more source

Phosphodiesterase 10A (PDE10A): Regulator of Dopamine Agonist-Induced Gene Expression in the Striatum. [PDF]

Cells, 2022
Bonate R, Kurek G, Hrabak M, Patterson S, Padovan-Neto F, West AR, Steiner H.   +6 more
europepmc   +1 more source